
When determining how to develop a bioprocess for your drug candidate, there are many key decisions about how to proceed including choosing a cell line, whether to outsource or keep in-house, and what type of bioprocess is most economic.
The old fed-batch and perfusion processes are well known but both have limitations. If you wish to move to a modern production platform, which one is best?
If you already have a facility this will impact significantly your cost base and therefore your choice, but today, most people wish to evaluate all opportunities that could reduce the cost of development and the cost of manufacture. Here is an overview about the four main process options commonly available. (note that batch processing is ignored here)
Typical questions may include:
Should I use fed-batch rather than perfusion? Which is lower cost? Which involves less risk? What about the concentrated perfusion processes? How do I know which process option is right for me?
…here are some ideas and answers:
Use Perfusion if you want to:
Use Concentrated Perfusion (Perfusion with the ATF System) if you want to:
Use Fed-Batch if you want to:
| Perfusion | Concentrated Perfusion | Fed-Batch | |
|---|---|---|---|
| Feed medium | Complete medium medium | Complete medium (multiple) | Feed concentrate medium |
| Environment | Constant | Constant | Changing |
| Osmolarity change | Constant | Constant | Increasing |
| Waste / toxic molecules | Removed | Removed | Accumulated |
| Product residence time | Low | Low | High |
| Stability of environment for product | High | High | Low |
| Typical Process Duration | 1-2 months | 1-2 months | 1-3 weeks |
| Typical cell concentration | 10-30m | 60-120m | 10-30m |
| Typical cell viability during production | 75-95% | 75-95% | 30-95% |
| Typical cell viability at harvest | 75-95% | 75-95% | 30-70% |
| Compatible with disposable reactors? | Yes | Yes | Yes |
| Compatible with Cell Banking™ with the ATF System? | Yes | Yes | Yes |
| Compatible with ATF-manufacturing™? | Yes | Yes | Yes |
| Seed train (litres) |
8 Stages: 1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L |
8 Stages: 1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L |
10 Stages: 1ml (vial), 5ml, 25ml, 125ml, 600ml, 3L, 15L, 75L, 400L, 2000L |
| Seed train with ATF-manufacturing™ Platform (litres) |
2 Stages: 100ml (bag), 10L |
2 Stages: 100ml (bag), 10L |
3 Stages: 100ml (bag), 10L, 500L |
| Typical manufacturing vessel size | 500L | 500L | 10,000L |
| Media cost per litre | Moderate | Moderate | High |
| Media volume required | High (1-2vvd) | High (1-2vvd) | Low (1vv) |
| Harvest | Daily / constant | Daily / constant | 1 per batch |
| Process control requirements | High | High | Moderate |
| Operation skill required | High | High | Moderate |
| Alkali addition | Low | Low | Moderate |
| §Compatible with continuous DSP | Yes | Yes | No |
| Output from 1000L reactor, per day | 0.2kg | 0.8kg | n-a |
| Output from 1000L reactor, per run (CHO cell data) | 6kg (20m cells per ml) (30 days) |
24kg (80m cells per ml) (30 days) |
1.2kg (peak 20m cells per ml) (14 days) |
| Time to produce 10Kg of product | 1-2 Batches ~7 weeks |
1 Batch ~2 weeks |
8-9 Batches ~22 weeks |
| Yearly output from 1000L reactor |
60kg (10 runs) |
240kg (10 runs) |
24kg (20 runs) |
| Reactor size required to produce ~250Kg oer year | 4x 1,000L | 1x 1,000L | 1x 10,000L |
§ Model data taken from CMC ICOS webinar 2009 presented through Bioprocess International (available in the download tab) and from one of Refine Technology’s pharmaceutical clients
| Perfusion * | Concentrated Perfusion * | Fed-Batch * | |
|---|---|---|---|
| Scale | 400L | 400L | 15,000L |
| Length | 50-180 days | 30-60 days | 15-20 days |
| Osmolarity change | 6-100 x 106 | 60-120 x 106 | 6-10 x 106 |
| Cell Line Stability | - | - | + |
| Product Concentration | +/- | + | + |
| Productivity | + | + | + |
| Product Residence Time | + | + | - |
| Process Simplicity | - | - | - |
| Process Control | - | - | - |
| Contamination Risk | - | - | + |
| Operation Costs | + | + | +/- |
* Data from CD-ROM Cell Retention and Perfusion, by Chun Zhang, Cell and Tissue Reactor Engineering, © 2003 University of Minnesota
** Data estimated on similar basis by Refine Technology
Feb
27
February 27 - February 29, 2012
4th Annual Disposable Solutions for Biomanufacturing
Brussels
Apr
02
April 02 - April 04, 2012
ISBioTech 2nd Annual Meeting
Virginia
Apr
11
April 11 - April 13, 2012
World Vaccine Congress 2012
Washington
Apr
18
April 18 - April 19, 2012
BioProcess International Europe 2012
Prague